# Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT

> **NCT00646321** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 540 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** budesonide/formoterol (Symbicort)
- **DRUG:** budesonide

## Key facts

- **NCT ID:** NCT00646321
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** 2004-08
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00646321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00646321, "Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00646321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*